The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Results of a phase III, randomized, double-blind, placebo-controlled trial of pegfilgrastim (PEG) in patients (pts) receiving first-line FOLFOX or FOLFIRI and bevacizumab (B) for colorectal cancer (CRC).
Tamas Pinter
No relevant relationships to disclose
Esteban Abella
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Alvydas Cesas
No relevant relationships to disclose
Adina Croitoru
Research Funding - Amgen
Jochen Decaestecker
No relevant relationships to disclose
Peter Gibbs
No relevant relationships to disclose
Yevhen Hotko
No relevant relationships to disclose
Jacek Jassem
No relevant relationships to disclose
Galina Petrova Kurteva
No relevant relationships to disclose
Jan Novotny
No relevant relationships to disclose
Seamus O'Reilly
Consultant or Advisory Role - Amgen (U)
Honoraria - Amgen
Research Funding - Amgen
Tomas Salek
No relevant relationships to disclose
May F. Mo
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
L. Mi Rim Choi
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Charles Davic Blanke
No relevant relationships to disclose